VistaGen Therapeutics, Inc., a biotechnology company, focuses on applying proprietary human pluripotent stem cell technology for technology for drug rescue, predictive toxicology, and drug metabolism screening. The company has developed CardioSafe 3D, a novel three-dimensional in vitro bioassay system for predicting in vivo cardiac effects, both toxic and non-toxic, of small molecule drug candidates before they are tested in animals or humans. It is also developing and validating LiverSafe 3D, a novel three-dimensional in vitro bioassay system for assessing liver toxicity and drug metabolism issues. In addition, the company product candidates include AV-101, an orally available small molecule that has completed Phase 1 development for the treatment of neurological disease and disorders market, including neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
April 30, 2018
RegMed Investors’ (RMi) closing bell; finally April is over
April 27, 2018
RegMed Investors’ (RMi) pre-open: watch your “six”
April 26, 2018
RegMed Investors’ (RMi) closing bell; a rally finish
April 24, 2018
RegMed Investors’ (RMi) closing bell; an embattled sector
April 23, 2018
RegMed Investors’ (RMi) closing bell; trading is very thin
45 companies, 1 interpreter!
Insight, foresight and recommendation
VistaGen (VTGN) – Started 2018 at $1.16, February saw $1.16 and March opened at $1.18 jumping to $1.47 on 3/6. Financing is always an issue yet it ended 2017 with $13 M in cash ...hold
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at email@example.com.
Editor and Publisher ... Henry McCusker enters his thirteenth (13th) year at RegMed Investors